Results 1 to 10 of about 24,588 (279)

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +2 more sources

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab [PDF]

, 2017
Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil ...
Allan, EG, Beavil, AJ, Ceska, T, Cossins, BP, Craggs, G, Davies, AM, Delgado, J, Henry, AJ, Keeble, AH, McDonnell, JM, Mitropoulou, AN, Pang, MOY, Sutton, BJ, Westwood, M   +13 more
core   +3 more sources

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome

Dermatology Practical & Conceptual, 2022
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo, Sara Cazzolla, Francesca Pampaloni, Mauro Alaibac   +3 more
doaj   +1 more source

Omalizumab-Associated Steatohepatitis

Actas Dermo-Sifiliográficas, 2023
Article disponible en castellà: http://hdl.handle.net/10230 ...
Barbosa, Joana, Coelho, Miguel B., Brasileiro, Ana, Giménez Arnau, Anna Maria   +3 more
openaire   +5 more sources

Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study

Frontiers in Immunology, 2022
BackgroundAllergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose.
Rui Tang, Shubin Lei, Liping Zhu, Yuzhen Lv, Hong Li   +4 more
doaj   +1 more source

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Clinical and Translational Allergy, 2021
Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended
Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen   +5 more
doaj   +1 more source

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria

CPT: Pharmacometrics & Systems Pharmacology, 2023
The pharmacokinetic (PK) characteristics of omalizumab and its pharmacodynamic (PD) effect in patients has yet to be fully characterized in chronic spontaneous urticaria, which could elucidate its pathogenesis and treatment response.
Elise Oh, Russ Wada, Kha Le, Yanan Zheng, Jin Jin, Victor Poon, Kit Wong, Ryan Owen, Kenta Yoshida   +8 more
doaj   +1 more source

Roles of omalizumab in various allergic diseases

Allergology International, 2020
IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and ...
Yoshimichi Okayama, Hisako Matsumoto, Hiroshi Odajima, Shunsuke Takahagi, Michihiro Hide, Kimihiro Okubo   +5 more
doaj   +1 more source

Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]

, 2016
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA, DUSE, MARZIA, Laitano, Rossella, LEONARDI, LUCIA   +3 more
core   +1 more source

Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis

Journal of International Medical Research, 2022
Omalizumab is used for the treatment of persistent severe allergic asthma in adults and children. However, some patients remain symptomatic even after omalizumab treatment. In bronchial asthma, chronic inflammation of the bronchial wall causes thickening
Mitsuru Tsuge, Masanori Ikeda, Yoichi Kondo, Hirokazu Tsukahara   +3 more
doaj   +1 more source